Here's Why United Therapeutics (UTHR) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
UTHR vs. STVN: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Drugs sector have probably already heard of United Therapeutics (UTHR) and Stevanato Group (STVN). But which of these two stocks is more attractive to value investors?
Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Is United Therapeutics (UTHR) Up 1.1% Since Last Earnings Report?
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?
United Therapeutics: Competitive Advantages At Such Cheap Multiples Scream Buy
UTHR's competitive advantages, including high returns on capital and successfully recycling of profits, support a bullish outlook. United Therapeutics' Q3 FY '24 earnings showed strong growth across major product lines, with Tyvaso, Orenitram, and Unituxin all posting significant YoY increases. My numbers project a 40% growth in earnings power for the business over the coming 2-3 years.
United Therapeutics Expands Into Organ Transplants, But Tyvaso's Legal Battles Loom
Despite legal challenges and exclusivity risks, United Therapeutics is a leader in PAH treatments, with Tyvaso being the primary revenue driver. UTHR is innovating in organ transplantation and bioengineered organs, including xenotransplantation and ex vivo lung perfusion, which could revolutionize the market. Legal battles, particularly with Liquidia, threaten United Therapeutics' intellectual property, affecting its Tyvaso franchise and competitive position in PAH.
United Therapeutics: One To Believe In Despite Competitive Threats
United Therapeutics Corporation's stock has surged over 300% since my 2020 “Buy” rating, driven by strong sales of Tyvaso DPI and other PAH treatments. Despite facing generic competition, United has maintained resilience, leveraging strategic litigation and innovative product development to protect and grow its revenue streams. United's future growth hinges on expanding Tyvaso DPI's market and advancing its pipeline, including promising IPF treatments and groundbreaking organ transplant technologies.
United Therapeutics (UTHR) is a Top-Ranked Growth Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
United Therapeutics (UTHR) is a Top-Ranked Value Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
United Therapeutics Q3 Earnings & Sales Beat Estimates
UTHR reports better-than-expected results in third-quarter 2024 on the back of strong demand for its treprostinil medications, especially Tyvaso.
United Therapeutics Corporation (UTHR) Q3 2024 Earnings Call Transcript
United Therapeutics Corporation (NASDAQ:UTHR ) Q3 2024 Earnings Conference Call October 30, 2024 9:00 AM ET Company Participants Dewey Steadman - Head of Investor Relations Martine Rothblatt - Chairperson & Chief Executive Officer Michael Benkowitz - President & Chief Operating Officer James Edgemond - Chief Financial Officer & Treasurer Leigh Peterson - Executive Vice President-Product Development & Xenotransplantation Conference Call Participants Joseph Thome - TD Cowen Roanna Ruiz - Leerink Partners Andreas Argyrides - Oppenheimer Roger Song - Jefferies Jessica Fye - JPMorgan Ash Verma - UBS Operator Good morning, and welcome to the United Therapeutics Corporation Third Quarter 2024 Earnings Webcast. My name is Dave, and I will be your conference operator today.
